|
|
Epigenomics AG Meets Key Milestone in Breast Cancer Test Development
 |
 |
| Date: Thursday, 12.08.2004 |
|
| Press Release, Berlin |
|
Berlin, Germany, August 12, 2004 - Epigenomics AG (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation, announced today that it has met a key milestone in its breast cancer screening product development program. Based on studies conducted using breast cancer tissue samples, the Company has successfully identified several DNA methylation markers (biomarkers) that can potentially enable the early detection of breast cancer. Biomarkers are substances found in blood or tissues that indicate the presence of disease. In this case, specific DNA methylation biomarkers allow detection of breast cancer using Epigenomics’ proprietary technologies. Achieving this milestone triggered a payment to Epigenomics from its development and commercialisation partner, Roche Diagnostics.
Epigenomics will work to incorporate these DNA methylation markers into PCR assays (tests) and initiate a study of a large number of clinical serum samples, taken from breast cancer patients, over the next several quarters. The breast cancer tests being developed will attempt to measure these biomarkers in blood serum to differentiate between breast cancer and benign or normal breast conditions.
Epigenomics believes that achieving this milestone on schedule demonstrates its ability to consistently meet commercially relevant product development milestones. To date, Epigenomics has successfully met every milestone in our collaboration with Roche, including the identification of DNA methylation markers for early detection products for colon and prostate cancers as well as for a product to predict the probability of relapse in women treated with the standard breast cancer treatment, tamoxifen.
For further information, please contact:
Epigenomics AG
Hong Thieu
VP Corporate Affairs
Phone: +49 30 24345 0
Fax: +49 30 24345 55
hong.thieu@epigenomics.com
Information for Description Area
This publication is not an offer for sale or a solicitation to purchase or subscribe for securities. The offer has been made exclusively by means of a prospectus. The German language sales prospectus (Verkaufsprospekt) dated July 2, 2004, the first supplement (Nachtrag) thereto dated July 15, 2004, the stock exchange admission prospectus (Börsenzulassungsprospekt) dated July 14, 2004 and the first supplement (Nachtrag) thereto dated July 16, 2004 may be obtained from Morgan Stanley Bank AG, Junghofstr. 13-15, 60311 Frankfurt am Main, from DZ BANK AG Deutsche Zentral-Genossenschaftsbank, Frankfurt am Main, Platz der Republik, 60265 Frankfurt am Main, from Lehman Brothers International (Europe), from Deutsche Börse AG, Abteilung Listing, Neue Börsenstrasse 1, 60487 Frankfurt am Main, and from Epigenomics AG, Kleine Präsidentenstrasse 1, 10178 Berlin. German residents may also download these documents from the web site of the company under http://www.epigenomics.com.
Publications with respect to possible stabilization measures and possible stabilisation consequences pursuant to Section 9(1) of the Regulation for the Implementation of the Prohibition on Market and Price Manipulation (Verordnung zur Konkretisierung des Verbotes der Kurs- und Marktpreismanipulation, \"KuMaKV\") have been made in the German language sales prospectus (Verkaufsprospekt) dated July 2, 2004, in the stock exchange admission prospectus (Börsenzulassungsprospekt) dated July 14, 2004, in a press release and through a publication on the internet at the address http://www.epigenomics.com. Stabilisation manager is Morgan Stanley Bank AG. |
|
| back |
|
top of the page
|
